1492 Capital Management’s Myriad Genetics MYGN Stock Holding History

1492 Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-29,786	Closed	-$866K	–	92
2018 Q4	$866K	Sell	29,786 -2,157	-7%	-$77.6K	0.78%	42
2018 Q3	$1.47M	Buy	31,943 +2,841	+10%	+$126K	0.96%	37
2018 Q2	$1.09M	Buy	29,102 +8,532	+41%	+$288K	0.78%	44
2018 Q1	$608K	Buy	+20,570	New	+$696K	0.47%	66
2015 Q1	–	Sell	-9,112	Closed	-$310K	–	144
2014 Q4	$310K	Hold	9,112	–	–	0.19%	90
2014 Q3	$351K	Sell	9,112 -385	-4%	-$14.4K	0.19%	85
2014 Q2	$370K	Buy	9,497 +262	+3%	+$9.75K	0.19%	87
2014 Q1	$316K	Sell	9,235 -1,361	-13%	-$42.2K	0.16%	97
2013 Q4	$222K	Buy	+10,596	New	+$268K	0.12%	121

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

1492 Capital Management's MYGN Position: Q1 2019 in Review

1492 Capital Management sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 29,786 shares — an estimated $866K sold.

1492 Capital Management first reported a position in MYGN in Q4 2013 and held it in 9 quarters. The position peaked at $1.47M in Q3 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

1492 Capital Management reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
1492 Capital Management sold 29,786 Myriad Genetics shares in Q1 2019, an estimated $866K.
1492 Capital Management first reported a position in Myriad Genetics in Q4 2013 and held it in 9 quarters.
1492 Capital Management's Myriad Genetics position peaked at $1.47M in Q3 2018.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on 1492 Capital Management's 13F filing for Q1 2019, filed 14 May 2019.